文献速递淋巴瘤造血干细胞移植与细胞治疗

liso-cel治疗复发/难治性CLL/SLL的1期TRANSCEND CLL 004研究

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
PubMed 文献 · Blood · 2022-01-01

TRANSCEND CLL 004是一项多中心、开放标签1/2期研究,报告liso-cel(一种自体CD19 CAR-T疗法)在复发/难治性CLL/SLL患者中的1期剂量递增部分结果。22例可评估疗效患者中总缓解率82%、完全缓解率45%。

要点

  • liso-cel在重度经治复发/难治CLL/SLL中显示高缓解率,总缓解率82%、完全缓解率45%。
  • 两个剂量水平安全性和疗效相似,2期部分采用100×10^6 CAR+ T细胞剂量进行中。

核心结论

  • liso-cel在复发/难治性CLL/SLL患者中展现出抗肿瘤活性,总缓解率82%、完全缓解率45%,且两个剂量水平安全性和疗效相似。

研究设计与样本

  • 多中心、开放标签1/2期TRANSCEND CLL 004研究(NCT03331198)的1期剂量递增部分。
  • liso-cel剂量为50×10^6或100×10^6 CAR+ T细胞。

主要发现

  • 22例可评估疗效患者中,总缓解率82%,完全缓解率45%。
  • 20例可评估MRD患者中,血和骨髓不可测MRD率分别为75%和65%。
  • 患者中位既往治疗线数为4线(范围2-11),100%既往接受伊布替尼,65%既往接受维奈克拉,83%具有高危特征包括TP53突变和del(17p)。

关键数值与推荐

  • 疗效评估依据2018年国际CLL工作组指南。
  • MRD评估在血液和骨髓中进行。

临床怎么用

  • liso-cel可为重度经治且BTKi和维奈克拉暴露后的复发/难治性CLL/SLL患者提供一种有效的CAR-T治疗选择。
  • 治疗相关细胞因子释放综合征和神经系统事件常见,需密切监测和管理。

局限性

  • 2期部分仍在进行中,最终疗效和安全性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). However, most patients eventually develop resistance to these therapies, underscoring the need for effective new therapies. We report results of the phase 1 dose-escalation portion of the multicenter, open-label, phase 1/2 TRANSCEND CLL 004 (NCT03331198) study of lisocabtagene maraleucel (liso-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory CLL/SLL. Patients with standard- or high-risk features treated with ≥3 or ≥2 prior therapies, respectively, including a BTKi, received liso-cel at 1 of 2 dose levels (50 × 106 or 100 × 106 CAR+ T cells). Primary objectives included safety and determining recommended dose; antitumor activity by 2018 International Workshop on CLL guidelines was exploratory. Minimal residual disease (MRD) was assessed in blood and marrow. Twenty-three of 25 enrolled patients received liso-cel and were evaluable for safety. Patients had a median of 4 (range, 2-11) prior therapies (100% had ibrutinib; 65% had venetoclax) and 83% had high-risk features including mutated TP53 and del(17p). Seventy-four percent of patients had cytokine release syndrome (9% grade 3) and 39% had neurological events (22% grade 3/4). Of 22 efficacy-evaluable patients, 82% and 45% achieved overall and complete responses, respectively. Of 20 MRD-evaluable patients, 75% and 65% achieved undetectable MRD in blood and marrow, respectively. Safety and efficacy were similar between dose levels. The phase 2 portion of the study is ongoing at 100 × 106 CAR+ T cells. This trial was registered at clinicaltrials.gov as NCT03331198.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Siddiqi T, Soumerai JD, Dorritie KA, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022. PMID: 34699592. doi:10.1182/blood.2021011895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。